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Abstract 58 
Background: Endocrine therapies are still the main strategy for the treatment of 59 
estrogen-receptor positive (ER+) breast cancers (BC) but resistance remains problematic. 60 
Cross-talk between ER and PI3K/AKT/mTORC has been associated with ligand-61 
independent transcription of ER. We have previously reported the antiproliferative effects 62 
of the combination of everolimus (an mTORC1 inhibitor) with endocrine therapy in 63 
resistance models, but potential routes of escape via AKT signalling can lead to 64 
resistance, therefore the use of dual mTORC1/2 inhibitors have met with significant 65 
interest.  66 
Methods: To address this, we tested the effect of vistusertib, a dual mTORC1 and 67 
mTORC2 inhibitor, in a panel of endocrine resistant and sensitive ER+ BC cell lines, 68 
with varying PTEN, PIK3CA and ESR1 mutation status. End-points included 69 
proliferation, cell signalling, cell cycle and effect on ER-mediated transcription. Two 70 
patient-derived xenografts (PDX) modelling endocrine resistance were used to assess the 71 
efficacy of vistusertib, fulvestrant or the combination on tumour progression and 72 
biomarker studies were conducted using immunohistochemistry and RNA-seq 73 
technologies. 74 
Results: Vistusertib caused a dose-dependent decrease in proliferation of all the cell lines 75 
tested and reduced abundance of mTORC1, mTORC2 and cell cycle markers, but caused 76 
an increase in abundance of EGFR, IGF1R and ERBB3 in a context dependent manner. 77 
ER-mediated transcription showed minimal effect of vistusertib. Combined therapy of 78 
vistusertib with fulvestrant showed synergy in two ER+ PDX models of resistance to 79 
endocrine therapy and delayed tumour progression after cessation of therapy.  80 
 5 
Conclusions: These data support the notion that models of acquired endocrine resistance 81 
may have a different sensitivity to mTOR inhibitor/endocrine therapy combinations. 82 
 83 
Keywords: breast cancer, estrogen receptor, mTORC1/2 signaling, vistusertib, endocrine 84 
resistance.  85 
 86 
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Background 88 
 89 
The largest proportion of patients diagnosed with primary breast cancer (BC) have 90 
tumours which develop in response to the female hormone estrogen. Classically, patients 91 
with estrogen receptor (ER) positive BC are treated with endocrine therapy such as 92 
aromatase inhibitors (AI), which block estrogen synthesis, or with estrogen antagonists 93 
such as tamoxifen or fulvestrant. Despite the efficacy of these agents, resistance to 94 
endocrine therapy remains a major clinical problem (reviewed by [1]). In vitro and in-95 
vivo studies suggest that cross-talk between the ER and growth factor signalling pathways 96 
can circumvent the need for steroid hormone. However, direct targeting of growth factors 97 
implicated in resistance has been met with limited success, largely as a result of tumour 98 
heterogeneity (reviewed  [2]).  99 
More recently, clinical studies have focused on targeting downstream of growth factor 100 
signalling, either by direct perturbation of PI3K/mTOR or CDK4/6 within the G1/S 101 
checkpoint. De-regulation of the PI3K/AKT/mTOR pathway has been strongly 102 
implicated in resistance to endocrine therapy. Loss of the tumour suppressor PTEN can 103 
lead to up-regulation of PI3K activity and has been associated with resistance to 104 
tamoxifen. Furthermore, up-regulation of growth factor signalling via IGFR can similarly 105 
increase activity, whilst loss of LKB1 can activate mTOR in a growth factor independent 106 
manner. The PI3K/AKT/mTOR can directly activate ER in a ligand-independent manner 107 
via phosphorylation of AF-1 at serine 167 of the ER. Furthermore, AKT has been shown 108 
to alter the ER-cistrome (genome-binding pattern) effectively changing the ER-109 
transcriptional program [3]. These bi-directional interactions between hormonal and 110 
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kinase signalling pathways potentiate pro-survival signals allowing BC cells to escape 111 
endocrine therapy blockade.  112 
Based upon these observations, targeting this pathway clinically in combination with 113 
endocrine therapy has proven attractive. The BOLERO-2 study, in which patients who 114 
had progressed on a non-steroidal AI were randomised to receive the steroidal AI 115 
exemestane alone or in combination with the mTORC1 inhibitor everolimus, showed a 116 
doubling in progression free survival in response to the combination [4], an observation 117 
supported by the phase II TAMRAD trial which showed everomilus in combination with 118 
tamoxifen was superior to single agent [5].  119 
Despite the efficacy of these agents, negative feedback-loops exist downstream of 120 
mTORC1 and lead to rapid tumour re-wiring resulting in increased activation of IGFR1-121 
dependent AKT activity, which in the long term may limit their effectiveness. In recent 122 
years, new generation dual mTORC1/2 inhibitors have been developed which have the 123 
potential to negate the mTORC1 associated feedback-loops [6], a concept recently tested 124 
in the MANTA trial [7].  125 
In this study, we explored the relevance of the dual mTORC1/2 inhibitor, vistusertib, in 126 
endocrine resistant and sensitive BC cell lines, as well as in patient derived xenograft 127 
(PDX) models and showed combination with fulvestrant had superior antiproliferative 128 
effects compared with fulvestrant alone. Furthermore, in a fulvestrant resistant PDX 129 
model, vistusertib resensitised the tumour to the antiproliferative effect of fulvestrant.  130 
 131 
 132 
 133 
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Methods 134 
Antibodies and Reagents 135 
The following primary antibodies were used in this study for immunoblotting: pRB
ser780 
136 
(CST-3590), pRB
ser807 
(CST-8516), total-RB (CST-9309), cyclin D1 (CST-2922), cyclin 137 
D3 (CST-2936), pAKT
ser473 
(CST-9271), pAKT
Thr308 
(CST-9275), total-AKT (CST-138 
9272), pEGFR
Tyr1068 
(CST-3777), total-EGFR (CST-2232), pERBB2
Tyr1248 
(CST-2243), 139 
total-ERBB2 (CST-4290), pERBB3
Tyr1222
 (CST-4784), pIGF1R
Tyr1135
 (CST-3918), 140 
pS6K
Ser235/236
 (CST-2211), total-S6K (CST-2217), Raptor (CST-2280), RheB (CST-141 
13879), p4EBP1
Thr37/46
 (CST-2855), 4EBP1 (CST-9452),  pSIN1
Thr86
 (CST-14716), SIN1 142 
(CST-12860), pER
ser167
 (CST-5587), Rictor (CST-2114) and Deptor (SCT-11816) were 143 
purchased from Cell Signalling Technology. p107 (sc-318), p130 (sc-317), total-ER (sc-144 
8002, F-10), ERBB3 (sc-415), IGF1R (sc-713) were purchased from Santa Cruz 145 
Biotechnology; -tubulin (T-9026) were from Sigma-Aldrich; Ki67 from Clinisciences. 146 
The following antibodies were used for immunohistochemistry: pERK1/2
Thr202/4
 (CST-147 
4370), pAKT
ser473 
(CST-4060), pS6K
Ser235/6
 (CST-4858), pmTOR
Ser2448
 (CST-2976) and 148 
p4EBP1
Thr37/46
 (CST-2855) were purchased from Cell Signalling Technology. Ki67 was 149 
purchased from clinisciences. Reagents were obtained from the following sources: 17-β-150 
estradiol (E2) and 4-hydroxytamoxifen (4-OHT) from Sigma-Aldrich; fulvestrant from 151 
Tocris; neratinib and vistusertib from SelleckChem. 152 
 153 
Cell Culture 154 
Human BC cell lines MCF7, SUM44, HCC1428, and T47D were obtained from the 155 
American Type Culture Collection, USA and Asterand. All cell lines were banked in 156 
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multiple aliquots to reduce the risk of phenotypic drift and identity confirmed using short 157 
tandem repeat (STR) analysis. Cells were routinely screened for mycoplasma 158 
contamination. Cells were maintained in phenol red-free RPMI1640 containing 10% 159 
foetal bovine serum (FBS) and 1nM estradiol (E2). Long-term estrogen derived (LTED) 160 
equivalents, modelling relapse on an AI were generated, as reported previously [8] and 161 
were maintained in phenol red-free RPMI1640 containing 10% charcoal-dextran stripped 162 
FBS (DCC). Tamoxifen-resistant (TAMR) MCF7 cells were generated by growing wild-163 
type MCF7 long-term in the presence of RPMI1640 containing 10% DCC + 0.01nM E2 164 
+ 100nM 4-OHT. Fulvestrant resistant (ICIR) MCF7 and MCF7 LTED cell lines were 165 
generated by growing parental cells long-term in the presence of RPMI1640 containing 166 
10% DCC + 1nM E2 + 100nM fulvestrant or RPMI1640 containing 10% DCC + 100nM 167 
fulvestrant, respectively. Palbociclib resistant (PalboR) cell lines were generated and 168 
maintained, as previously described [9, 10]. All cell lines were stripped of steroids for 48-169 
72-hours prior to the start of experiments.  170 
 171 
Proliferation Assays 172 
Cells were seeded into 96-well tissue culture plates and allowed to attach overnight. 173 
Monolayers were then treated with increasing concentrations of the drugs and after 72-174 
hours cell viability was determined using the CellTitre-Glo® Luminescent Cell Viability 175 
Assay (Promega), according to the manufacture’s protocol. Values were expressed as 176 
relative luminescence compared to the vehicle treated control. Non-linear regression 177 
analysis was used to fit the curves and IC50 values were calculated using PRISM 7 178 
software (Graphpad). To determine the nature of the interaction between vistusertib and 179 
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fulvestrant, combination studies were performed by using Chou and Talalay’ s constant 180 
ratio combination design and quantified using Calcusyn software (BIOSOFT, Cambridge, 181 
UK) [11]. The combination indices (CI) were obtained by using mutually nonexclusive 182 
Monte Carlo simulations. In this analysis, CI scores significantly lower than 1 were 183 
defined as synergistic; CI > 1, as antagonistic; and a CI = 1, as additive.  184 
 185 
Immunoblotting 186 
All cells were grown in the presence of RPMI1640 containing 10% DCC for 3 days prior 187 
to seeding. Cells were seeded into dishes, allowed to attach overnight and treated with the 188 
appropriate drugs the following day. After 24 hours treatment, total protein was extracted 189 
and immunoblotting carried out, as previously described [8].  190 
 191 
Real-time Quantitative PCR  192 
mRNA from treated cells and from HBCx34 OvaR PDX models (n=30; [12]) was 193 
extracted using RNeasy Mini Kit (Qiagen), quantified and reverse-transcribed with 194 
SuperScriptIII First Strand Synthesis System (Invitrogen). Taqman gene expression 195 
assays (Applied Biosystems) were used to quantify TFF1 (Hs00907239_m1), PGR 196 
(Hs01556702_m1), GREB1 (Hs00536409_m1), PDZK1 (Hs00275727-m1) and ESR1 197 
(Hs01046818_m1), EGFR (Hs01076090_m1), ERBB2 (Hs01001580_m1), ERBB3 198 
(Hs00176538_m1), IFG1R (Hs00609566_m1) and/or IRS1 (Hs00178563_m1) together 199 
with FKBP15 (Hs00391480_m1) as housekeeping gene to normalise the data. The 200 
relative quantity was determined using ΔΔCt, according to the manufacturer's instructions 201 
(Applied Biosystems). 202 
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 203 
In vivo Patient-derived Xenografts 204 
HBCx22 OvaR and HBCx34 OvaR PDX models resistant to endocrine therapy were 205 
established as stated previously [12], in accordance with the French Ethical Committee. 206 
Efficacy studies were carried out to determine the anti-tumour activity of vistusertib 207 
alone and combined to fulvestrant administered over 90 days. The treatment groups (10-208 
12 mice per arm) received either vistusertib (15 mg/kg daily by oral gavage) or 209 
fulvestrant (5mg/mouse suspended in corn oil by weekly subcutaneous injection into the 210 
flank). These concentrations are in keeping with previous studies [6] and clinical 211 
achievable doses [13] for vistusertib. For the combination group, fulvestrant was dosed 2 212 
hours before administration of vistusertib. The control groups received both vehicles. To 213 
assess whether treatment with vistusertib alone or in combination with fulvestrant could 214 
further delay tumour progression, five mice from each group were followed for an 215 
additional 40 days after drug withdrawal. 216 
Tumour diameters were measured using calipers and volumes were calculated as V= a x 217 
b2/2, where "a" is the largest diameter and "b" is the smallest. Percent change in tumour 218 
volume was calculated for each tumour as (Vf - V0/V0) x 100, where V0 is the initial 219 
volume (at the beginning of treatment) and Vf is the final volume (at the end of 220 
treatment). Tumour regression (R) was defined as a decrease in tumour volume of at least 221 
50% taking as reference the baseline tumour volume [14]. 222 
Tumour volumes were expressed relative to the initial starting volume (relative tumour 223 
volume (RTV)). Tumour growth inhibition (TGI) from the start of treatment was 224 
calculated as the ratio of the mean RTV between control and treated groups measured at 225 
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the same time. Because the variance in mean tumour volume data increases 226 
proportionally with volume (and is therefore disproportionate between groups), data were 227 
log-transformed to limit any size dependency before statistical evaluation. Statistical 228 
significance of TGI was calculated by the paired Student t test by comparing the 229 
individual RTVs in the treated and control groups.  230 
 231 
Immunohistochemistry  232 
In order to assess biomarker changes, a pharmacodynamic study was performed for 4 233 
days of treatment with vistusertib, fulvestrant or a combination of the two drugs in the 234 
HBCx22 OvaR PDX model. Mice were sacrificed at 4 hours after the final treatment and 235 
tumours resected. Excised tumours were fixed in 10% neutral buffered formalin, paraffin 236 
embedded and tissue microarrays (TMA) were built from the blocks. Three xenografts 237 
from each treatment group and two tissue cores per tumour were included in the TMA. 238 
Sections from the TMA were cut and stained for the expression of biomarkers, as 239 
previously described [12]. The immunohistochemically stained TMA sections were 240 
digitally scanned at ×20 with a Hamamatsu NanoZoomer‐ XR whole-slide scanner 241 
(Hamamatsu Photonics K.K., Hamamatsu, Japan). The quality of the images was checked 242 
manually and the images were analysed with Visiopharm integrator system (VIS) version 243 
2018.9.3.5303 (Visiopharm A/S) using VIS ready to use automated image analysis 244 
algorithms (APPs). 245 
 246 
RNA-seq  247 
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Excised tumours from HBCx34 OvaR PDX sacrificed mice were used for a gene 248 
expression study (n=12; 3 mice by group). Libraries were created after using Truseq 249 
Stranded mRNA Library Prep Kit (Illumina) and sequenced using the NextSeq500 250 
(Illumina). RNA-seq data was aligned to human GRCh38 reference genome using STAR 251 
Aligner (star v2.6.1a)  [15], read count for each gene were calculated with htseq (v0.6.1) 252 
[16]. Genes were compared for differential expression between the different treatments 253 
using edgeR [17], and were considered to be statistically expressed when absolute fold-254 
change >= 2 and FDR < 5%. These significantly expressed gene lists were subject to 255 
further functional annotation using Ingenuity Pathway Analysis (IPA) to identify altered 256 
pathways due to the corresponding treatments. For individual pathways, the Benjamini–257 
Hochberg procedure was used to the calculate false discovery rate (FDR) in order to 258 
adjust for multiple testing. RNA-seq data supporting the findings was deposited in the 259 
NCBI (http://ncbi.nlm.nih.gov/geo/) with reference PRJNA564917. 260 
 261 
 262 
Results 263 
Inhibitory effects of vistusertib on BC cell proliferation 264 
We tested the antiproliferative effect of vistusertib in a panel of isogenic cell lines 265 
modelling sensitivity or resistance to endocrine therapy (MCF7, SUM44, HCC1428 and 266 
T47D) for which the PIK3CA, PTEN and ESR1 mutation status was previously 267 
established [18, 19]. Assays were conducted in the presence of E2, to model the effects of 268 
vistusertib as a monotherapy, or in the absence of E2, to model the combination with an 269 
AI in the primary setting. MCF7 cells showed a concentration dependent decrease in 270 
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proliferation in the presence of E2 with an IC50 of 20nM. In the absence of E2, minimal 271 
further antiproliferative effect was evident from the addition of vistusertib and the IC50 272 
was increased (Figure 1a, Additional File 1: Table 1a). In an extended panel of ER+ cell 273 
lines, in the presence of E2, vistusertib sensitivity varied with IC50 values between 30-274 
500nM (Additional File 2: Figure S1a and Additional File 1: Table 1a). Removal of 275 
E2 caused a drop in proliferation in all cell lines, as expected. Addition of vistusertib 276 
further reduced cell viability in a dose dependent manner (IC50 values between 40-277 
700nM; Additional File 2: Figure S1a and Additional File 1: Table 1a). In order to 278 
assess the effect of vistusertib in cell lines modelling resistance to an AI, escalating 279 
concentrations were tested in two MCF7 LTED models in the presence or absence of E2. 280 
Of note, the MCF7 LTED
Y537C
, which harbour a hotspot ESR1 mutation in the ligand-281 
binding domain, showed sensitivity with an IC50 of 50nM in the presence or absence of 282 
E2, in keeping with their ligand independent phenotype (Figure 1b). Contrastingly, 283 
MCF7 LTED
wt
 showed an IC50 slightly higher (75nM) (Figure 1c). Three further LTED 284 
cell lines were assessed. HCC1428 LTED expressing wild-type (wt) ESR1, SUM44 285 
LTED harbouring ESR1
Y537S
 and T47D LTED which lose ER expression showed varying 286 
IC50 values between 65-350nM (Additional File 2: Figure S1b and Additional File 1: 287 
Table 1a).  288 
We further assessed sensitivity to vistusertib in cell lines modelling resistance to 289 
tamoxifen (TAMR) or fulvestrant (ICIR). In keeping with the previous data, both models 290 
showed a concentration-dependent decrease in proliferation with IC50 values of 85nM and 291 
50nM, respectively (Figure 1d-e and Additional File 1: Table 1b). Finally, we assessed 292 
the effect of escalating doses of fulvestrant both in the presence or absence of a fixed 293 
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concentration of vistusertib in MCF7 LTED
wt
 and MCF7 LTED
Y537C 
cell lines (Figure 1f-294 
g and Additional File 1: Table 1c). In both cell line models, the combination with 295 
vistusertib appeared synergistic with combination index below 1.  296 
These data suggest that vistusertib may provide benefit in combination with an AI in 297 
patients with de novo endocrine resistance and showed efficacy in models of acquired 298 
endocrine resistance irrespective of ESR1 mutation status or ESR1 protein abundance.  299 
 300 
Effect of vistusertib on receptor tyrosine kinase and downstream signalling 301 
pathways. 302 
Previous studies have shown that blockade of mTORC1 can lead to feedback loops via 303 
IGFR and ERBB signalling networks [20, 21] (Figure 2a). In order to test the effect of 304 
targeting both mTORC1 and mTORC2, we examined the effect of vistusertib upon key 305 
protein targets within the mTOR pathway. Immunoblot analysis of the MCF7 and LTED 306 
derivatives was assessed (Figure 2b). Vistusertib caused a decrease in expression of 307 
pS6RP
Ser235/6
, p4EBP1
Thr37/46
 and pAKT
Ser473 
and an increase in Deptor and pSin1 308 
together with a decrease in abundance of Cyclin D1, D3 and pRB indicative of cell cycle 309 
arrest. Treatment with fulvestrant alone or in combination with vistusertib reduced 310 
abundance of both phosphorylated and total ER. Despite the dual blockade of 311 
mTORC1/2, feedback loops via IGF1R and ERBB family members were evident but 312 
appeared cell line specific. For instance, MCF7 LTED
wt
 showed marked increases in 313 
pIGF1R and pAKT
Thr308
 in response to vistusertib. To test if the effect of vistusertib was 314 
persistent beyond a 24 hours period, we performed a time course experiment and showed 315 
 16 
a gradual increase in abundance of pEGRF, pIGF1R and pSin1 markers up to 96 hours of 316 
treatment (Additional File 3: Figure S2) 317 
 318 
Effect of vistusertib alone or in combination with fulvestrant on ER-mediated 319 
transcription 320 
Evidence suggests that cross-talk between PI3K/AKT/mTOR impacts on ER function as 321 
a transcription factor. Indeed, mTORC1 via S6RP has been shown to phosphorylate ER at 322 
serine 167 [22]. We therefore assessed the effects of vistusertib on ER-mediated 323 
transcription. The relative expression of a panel of estrogen-regulated genes (ERGs: 324 
TFF1, PGR, GREB1 and PDZK1) was evaluated in the presence or absence of E2. In 325 
MCF7 and in both MCF7 LTED derivatives, treatment with vistusertib under DCC 326 
conditions, caused subtle or no changes in expression of ERGs that was gene- and cell-327 
specific (Additional File 4: Figure S3). Similarly, in the presence of 0.01nM of E2, 328 
vistusertib caused small changes in the expression of the ERGs for all the three cell lines 329 
tested, but fulvestrant alone or in combination with vistusertib consistently reduced 330 
expression of all the ERGs when compared with the vehicle control (Figure 3). These 331 
data suggest that vistusertib does not impact in ER-mediated transcription. 332 
 333 
Vistusertib in combination with fulvestrant impedes tumour progression in human 334 
BC PDX models of acquired endocrine resistance 335 
In order to assess the effect of vistusertib alone or in combination with fulvestrant in vivo, 336 
we adopted two PDX models of acquired endocrine resistant BC. HBCx34 OvaR is an 337 
ER+ PDX which is resistant to E-deprivation and tamoxifen but sensitive to the anti-338 
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proliferative effects of fulvestrant [12] (Figure 4). After a period of 64 days, all 339 
treatments showed over a 95% reduction in tumour volume (fulvestrant: 97.6%, p=0.004; 340 
vistusertib: 96.2%, p<0.0001; combination: 99.7%, p<0.0001) compared to vehicle 341 
control (Figure 4a and Additional File 5: Figure S4). Vistusertib showed greater 342 
efficacy than fulvestrant as a monotherapy over the first 50 days (adjusted p-value=0.005) 343 
and appeared similar to the combination over this time period. At the end of treatments, 344 
all xenografts were in regression or complete response in the combination arm (% of 345 
tumour volume change  50%), against 4 xenografts in the fulvestrant-treated group 346 
(Figure 4a). 347 
Analysis of the combination of vistusertib and fulvestrant appeared the most effective 348 
showing a significant increase in efficacy compared to fulvestrant alone (p=0.0001, 349 
Mann-Whitney test, Figure 4a).  350 
In order to further explore the impact of vistusertib alone or in combination with 351 
fulvestrant, tumours were resected at the end of the study and subjected to RNA-seq. 352 
Fulvestrant showed the greatest impact on gene expression (1456 upregulated and 1077 353 
downregulated genes) versus vistusertib (291 upregulated and 174 downregulated genes) 354 
when compared with vehicle control (Figure 4b). Noteworthy, the number of gene 355 
changes as a result of the combination largely reflected that seen for fulvestrant (1717 356 
upregulated and 1412 downregulated genes) indicating the mitogenic driver within this 357 
PDX remains ER. In order to identify canonical pathways affected by these treatments, 358 
we conducted ingenuity pathway analysis (IPA; FDR< 5%) using differentially expressed 359 
genes (FDR < 5% and fold-change >=2; Additional File 6: File S1). Fulvestrant showed 360 
a dominant effect on cell cycle and estrogen-mediated S-phase entry both as a 361 
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monotherapy or in combination with vistusertib. Contrastingly, single agent vistusertib 362 
showed no impact on ER-mediated S-phase entry. Treatment with vistusertib showed 363 
minimal although significant enrichment of EGF, ERBB, and ERK/MAPK signalling 364 
compared with vehicle control (Additional File 6-File S1). In order to explore this 365 
further, we carried out targeted qRT-PCR (Figure 4c). Treatment with fulvestrant 366 
significantly reduced expression of TFF1, PGR, GREB1, IRS1 but increased expression 367 
of EGFR, ERBB2 and ERBB3. Contrastingly, vistusertib had minimal effect on 368 
expression of ESR1, GREB1 and PGR; however, it significantly reduced TFF1 but not to 369 
the degree seen with fulvestrant or the combination. Noteworthy, vistusertib significantly 370 
increased expression of EGFR but not ERBB2, ERBB3 or IGF1R.  371 
In order to further explore the efficacy of the combination of vistusertib with fulvestrant, 372 
a second PDX model, HBCx22 OvaR, was assessed. HBCx22 OvaR is an ER+ model 373 
showing partial resistance to fulvestrant and harbours a 24 base-pair in-frame deletion in 374 
exome 13 in PIK3R1 [12] (Figure 5). As expected, single agent fulvestrant had no 375 
significant impact on tumour progression compared to vehicle control, confirming the 376 
resistant phenotype. Vistusertib as a monotherapy delayed tumour progression by 54.5% 377 
(p=0.04) compared to vehicle control. The combination of vistusertib plus fulvestrant was 378 
the most effective treatment with tumour volumes 84.7% lower than vehicle control 379 
(p=0.0002) (Figure 5a). After 93 days of treatment, the therapies were withdrawn and the 380 
tumour volumes assessed for a further 40-days in order to establish the efficacy of the 381 
drugs in delaying tumour progression (Figure 5b). Removal of therapies showed 382 
sustained anti-tumour effect in the combination group, whilst, tumours treated with 383 
vistusertib alone showed significant progression. 384 
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In order to assess dynamic changes, three mice per arm were sacrificed after 4 days of 385 
therapy and tissue sections were subjected to immunohistochemical analysis. Treatment 386 
with vistusertib or vistusertib in combination with fulvestrant revealed suppression of 387 
pAKT
Ser473
, p4EBP1
Thr37/46
 and pS6RP
Ser235/6
, as well as a slight but noticeable decrease 388 
in pmTOR
Ser2448
 (Figure 5c and Additional File 7: Figure S5a). Furthermore, fulvestrant 389 
reduced expression of pERK1/2
Thr202/4
 both alone and in combination with vistusertib. In 390 
contrast to our in vitro analysis, no alteration in abundance of pEGFR and pIGFR were 391 
evident in response to vistusertib alone, whilst pEGFR was significantly suppressed by 392 
the combination with fulvestrant (Additional File 7: Figure S5b). Noteworthy, 393 
assessment of Ki67 showed the greatest reduction when the combination of vistusertib 394 
and fulvestrant was used (Additional File 7: Figure S5a). 395 
Taken together, these data suggest the combination may provide greater efficacy than 396 
fulvestrant alone in ER+ acquired endocrine resistant disease. 397 
 398 
Effectiveness of vistusertib in combination with pan-ERBB inhibitors and in models 399 
of resistance to palbociclib 400 
As increased feedback loops via ERBB and IGF1R family members were evident in vitro 401 
and from our gene expression analysis, we assessed sensitivity of MCF7-LTED
wt
 cell 402 
lines to the antiproliferative effect of vistusertib, or fulvestrant combined with the pan-403 
ERBB inhibitor neratinib, or  the combination of all three agents (Figure 6a). Fulvestrant 404 
and neratinib enhanced the antiproliferative effect of vistusertib, however, the triple 405 
combination was most effective. These data further support previous observations in 406 
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which the triple combination targeting three cellular nodes: ERBB, ER and mTORC1 407 
showed greatest antiproliferative effect [20]. 408 
 409 
More recently, CDK4/6 inhibitors have become the standard of care in the treatment of 410 
endocrine resistant ER+ BC. Despite their efficacy, not all patients benefit and many will 411 
eventually relapse with acquired resistance. Studies suggest that cross-talk exists between 412 
CDK4 and the mTOR pathway via pTSC2 [23] and that blockade of mTORC1/2 may 413 
delay onset of resistance to CDK4/6 inhibition [24]. To assess this, we treated three 414 
palbociclib resistant cell line models (MCF7-
PalboR
, MCF7 LTED-
PalboR
 and T47D-
PalboR
) 415 
(Figure 6b) with escalating concentrations of vistusertib with or without fulvestrant. All 416 
three cell lines showed sensitivity to mTORC1/2 blockade. The addition of fulvestrant 417 
further enhanced the antiproliferative effect. Taken together these data suggest 418 
mTORC1/2 blockade remains effective after acquisition of resistance to palbociclib. 419 
 420 
Discussion 421 
Cross-talk between the PI3K/AKT/mTOR pathway and ER is well documented and 422 
targeting this pathway with mTORC1 inhibitor, everolimus, has shown marked efficacy 423 
[25]. However, negative feedback loops have been identified leading to activation of 424 
growth factor signalling pathways and reduced drug sensitivity [21] [20]. In this study, 425 
we assessed the efficacy of the mTORC1/2 inhibitor, vistusertib, in vitro and in PDX 426 
models of endocrine resistance. In summary, we show that vistusertib as a monotherapy 427 
had little impact on global gene expression compared to fulvestrant and did not 428 
significantly impact on ER-mediated transactivation. These findings are in contrast to 429 
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previous studies which have shown that inhibition of PI3K leads to an open chromatin 430 
state at estrogen target loci resulting in enhanced ER-mediated transactivation, supporting 431 
the concept of combined PI3K and endocrine therapies [26]. However, our observations 432 
are in keeping with a recent study which explored the impact of mTORC suppression on 433 
the genome wide recruitment of ER which showed no alteration in binding patterns 434 
compared to vehicle control [24]. This would suggest that direct cross-talk may be 435 
restricted to PI3K and AKT [26] [3].  436 
Vistusertib as a single agent significantly suppressed the abundance of pS6 and p4EBP1 437 
both in vitro and in vivo. In contrast to our previous studies with everolimus [20] [21], 438 
vistusertib decreased abundance of pAKT
ser473
, whilst increasing pAKT
thr308
 indicative of 439 
efficient suppression of both mTORC1 and mTORC2 activity. In addition, AZD2014 440 
may display different target engagement properties from everolimus, which may in turn 441 
lead to different clinical efficacy. Nonetheless, we found evidence of increased 442 
expression of pEGFR and pIGF1R in a context specific manner suggesting that tumour 443 
re-wiring and feedback loops previously associated with poor response to mTORC1 444 
suppression, were evident. However, despite this, cell proliferation was significantly 445 
reduced both in vitro and in vivo. Moreover, the enhanced expression of growth factor 446 
receptors, in particular members of the ERBB family, were far more pronounced with 447 
fulvestrant.  448 
There are two underlying mechanisms by which EGFR can be increased in this context. 449 
Firstly, suppression of mTOR leads to loss of phosphorylated TCS2 and suppression of 450 
S6, leading to the removal of the negative feedback loop resulting in increased expression 451 
of EGFR [23]. Conversely, ER is known to cross-talk with EGFR/ERBB2 and studies 452 
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suggest that ER sequesters the coactivators AIB1 and SRC1 leading to the suppression of 453 
ERBB2 signalling, whilst in the presence of fulvestrant, downregulation of ER-function 454 
would lead to the converse [27] [28]. Despite this early re-wiring, the combination of 455 
vistusertib and fulvestrant showed enhanced anti-tumour activity which was maintained 456 
even after cessation of drug in PDX model resistant to fulvestrant. 457 
It is noteworthy, in our HBCx34 model which is PTEN competent and ER+, that ER 458 
expression remains the dominant mitogenic driver. In this context, mTORC1/2 459 
suppression is sufficient to impede tumour progression, most likely as the PI3K pathways 460 
is not hyperactivated. In addition, this PDX is sensitive to fulvestrant and thus combining 461 
blockade of ER and mTORC1/2 significantly impedes tumour progression. Contrastingly, 462 
HBCx22 shows hyperactivation of the PI3K/AKT/mTOR pathway as a result of a 463 
PIK3R1 frameshift and despite continuing to express high levels of ER, is resistant to 464 
fulvestrant. In this setting, monotherapy targeting ER or mTORC1/2 is insufficient to 465 
have prolonged anti-tumour effect whilst the combination targeting both pathways 466 
suppresses tumour progression even after cessation of therapy.  467 
The recent MANTA trial explored the concept of targeting both ER and mTORC1/2 in 468 
patients with primary and secondary AI therapy resistant disease. Patients were 469 
randomised to single agent fulvestrant versus fulvestrant in combination with vistusertib 470 
or everolimus. Although not significant, the combination of vistusertib plus fulvestrant 471 
showed a trend towards improved progression free survival in the first year compared to 472 
fulvestrant as a single agent (median 7.6-8.0 versus 5.4 months). However, the 473 
combination of fulvestrant plus everolimus appeared superior increasing progression free 474 
survival from 5.4 to 12.3 months [7]. The lack of a significant effect of the combination 475 
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of vistusertib plus fulvestrant compared to everolimus may reflect the differences in 476 
target engagement properties for the two compounds, or alternatively different 477 
dependency of patients who have relapse on AI therapy on mTORC1 signalling. These 478 
data are in contrast to those seen in our PDX models and one explanation could be that 479 
prior treatment influences responses to secondary combinations. For instance, the most 480 
powerful antiproliferative effects seen in our study was associated with resistance to 481 
fulvestrant. This suggests that in patients with acquired resistance, previous lines of 482 
endocrine therapy should be considered to guide treatment choices 483 
Lastly, as noted, CDK4/6 inhibitors are changing the face of therapy for ER+ BC ([29, 30], 484 
however, not all patients will respond, and many will acquire resistance. Previous studies have 485 
shown that the combination of mTORC1/2 inhibition with a CDK4/6 inhibitor enhances E2F 486 
suppression and delays onset of resistance as well as circumventing it [24]. In order to 487 
corroborate these observations we assessed vistusertib sensitivity in a panel of cell lines with 488 
acquired resistance to palbociclib [9, 10]. Unlike the previous study, our cell lines utilised 489 
different resistance mechanisms including loss of RB copy number (T47D-
PalboR
) and tumour re-490 
wiring via increased growth factor signalling (MCF7-
PalboR
 and MCF7-LTED
PalboR
). Vistusertib 491 
effectively suppressed the proliferation of all models tested and this effect was enhanced by the 492 
addition of fulvestrant. These data provide further support for the concept that mTORC1/2 493 
inhibitors may provide utility after acquisition of resistance to CDK4/6 inhibitors. 494 
 495 
Conclusion 496 
In summary, our data suggests that suppression of mTORC1 and mTORC2 has no 497 
significant impact on ER-mediated transcription but combination therapy with fulvestrant 498 
shows synergistic benefit.  Patients with secondary acquired resistant ER+ BC may have 499 
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different sensitivities to mTOR inhibition in combination with endocrine therapy. Finally, 500 
mTORC1/2 inhibitors may provide utility after relapse on CDK4/6 inhibitors. 501 
 502 
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 663 
Figure Legends 664 
Figure 1. Effect of vistusertib alone or in combination with endocrine agents in 665 
several cell line models of endocrine sensitivity and resistance BC. (a-c) Effect of 666 
escalating doses of vistusertib on proliferation of (a) MCF7, (b) MCF7 LTED
Y537C
 and 667 
(c) MCF7 LTED
wt
 cell lines in the absence and in the presence of 0.01nM E2. (d-e) 668 
Effect of escalating doses of vistusertib on proliferation of (d) tamoxifen (MCF7 TAMR) 669 
and (e) fulvestrant resistant (MCF7 ICIR and MCF7 LTED ICIR) cell lines. (f-g) Effect 670 
of escalating doses of fulvestrant in the presence or absence of 75nM of vistusertib on 671 
both (f) MCF7 LTED
wt
 and (g) MCF7 LTED
Y537C
 (left panels) and respective 672 
combination index heatmaps (right panels). Data are expressed as luminescence relative 673 
to vehicle control. Cell viability was analysed using a CellTiter-Glo assay. Error bars 674 
represent mean ± SEM. 675 
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 676 
Figure 2. Effect of vistusertib on RTKs and downstream signalling pathways. (a) 677 
Schematic representation of the PI3K/AKT/mTOR signalling pathway and cross-talk 678 
with RTKs. (b) Effect of vistusertib alone on in combination with fulvestrant on 679 
mTORC1, mTORC2, cell cycle, ER and RTKs targets, both in the presence or absence of 680 
0.01nM E2.  681 
 682 
Figure 3. Effect of vistusertib alone or in combination with fulvestrant in ER-683 
mediated transcription. MCF7, MCF7 LTED
wt 
and MCF7 LTED
Y537C
 were treated in 684 
the presence of 0.01nM E2 with vistusertib, fulvestrant or the combination for 24-hours 685 
and effects on TFF1, PGR, GREB1 and PDZK1 were assessed by RT-qPCR. Error bars 686 
represent means ± SEM. Vist= vistusertib; Fulv= fulvestrant, Vist + Fulv= combination 687 
treatment. 688 
 689 
Figure 4. Effect of vistusertib alone or in combination with fulvestrant on tumour 690 
progression in HBCx34 OvaR PDX models. (a) Long-term study assessing changes in 691 
tumour volume over 64 days of treatment in HBCx34 OvaR. HBCx34 OvaR is an ER+ 692 
PDX model which is resistant to E-deprivation and tamoxifen but sensitive to the anti-693 
proliferative effects of fulvestrant. Mice were treated with vehicle control, fulvestrant, 694 
vistusertib or the combination and data shows median tumour volume (mm
3
). Bars 695 
represent % of volume change at the end of treatment compared with baseline, for each 696 
individual animal. (b) Venn diagram showing the intersect of genes up and 697 
downregulated for the different treatments by RNA-seq analysis; tumours of three 698 
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animals by group were evaluated. (c) Effect of vistusertib (n=10), fulvestrant (n=8) or the 699 
combination (n=3) in relation to vehicle (n=9) upon relative RNA expression of ERGs 700 
and RTKs by RT-qPCR. Error bars represent means ± SEM. Statistical analysis was 701 
performed using Anova with Dunnett's multiple comparisons test. 

Tendency to 702 
difference between groups by t-test. Vist= vistusertib; Fulv= fulvestrant, Vist + Fulv= 703 
combination treatment. 704 
 705 
Figure 5. Effect of vistusertib alone or in combination with fulvestrant on tumour 706 
progression in HBCx22 OvaR PDX models. (a) Long-term study assessing changes in 707 
tumour volume over 93 days of treatment in HBCx22OvaR. HBCx22 OvaR is an ER+ 708 
model that shows partial resistance to fulvestrant. Mice were treated with vehicle control, 709 
fulvestrant, vistusertib or the combination. Data represents mean relative tumour volume 710 
± SEM. (b) Effect of vistusertib alone or in combination with fulvestrant on tumour 711 
growth of individual mice over a period of 93 days. Treatments were withdrawn and 712 
tumour growth reassessed for a further 40 days to establish the efficacy of the drugs in 713 
delaying tumour progression. (c) Immunohistochemical analysis of several markers 714 
following treatment for a period of 4 days with either vehicle, vistusertib (Vist), 715 
fulvestrant (Fulv) or the combination of both (Vist + Fulv). Tumours were harvest 4 716 
hours after last treatment. Statistical analysis was performed using ANOVA with 717 
Dunnett's multiple comparisons test. 

Tendency to difference between groups by t-test.  718 
 719 
Figure 6. Effect of vistusertib in combination with neratinib/ fulvestrant in cell line 720 
models of endocrine and palbociclib resistance BC. (a) Effect of escalating doses of 721 
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vistusertib in combination with fulvestrant (1nM) (Fulv) and neratinib (500nM) on 722 
proliferation of MCF7 LTED
wt
 cell lines in the presence of 0.01nM E2. Data are 723 
expressed as percentage of viable cells relative vehicle control. (b) Effect of escalating 724 
doses of vistusertib with or without fulvestrant (1nM) on proliferation of palbociclib 725 
resistant cell lines MCF7
PalboR
, MCF7 LTED
PalboR 
and T47D
PalboR
 cell lines. Data 726 
expressed as luminescence. Error bars represent mean ± SEM. 727 
 728 
Additional Files 729 
Additional File 1: Table S1a-c. IC50 values for antiproliferative effect of (a) vistusertib 730 
for several endocrine sensitive and resistant cell line models both in the presence or 731 
absence of 0.01nM E2, (b) vistusertib in cell line models of resistance to tamoxifen 732 
(TAMR) and fulvestrant (ICIR); (c) fulvestrant alone or in combination with 75nM of 733 
vistusertib in the presence of 0.01nM E2. 734 
 735 
Additional File 2: Figure S1. Effect of vistusertib in models of endocrine sensitive 736 
and resistant BC. (a) Effect of escalating doses of vistusertib on proliferation of 737 
endocrine sensitive (HCC1428, T47D and SUM44) and (b) endocrine resistant 738 
(HCC1428 LTED, T47D LTED and SUM44 LTED
Y537S
) cell line models both in the 739 
absence and in the presence of 0.01nM E2. Data are expressed as relative luminescence 740 
and represented as fold-change relative to vehicle DCC control for each cell line 741 
condition.  742 
 743 
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Additional File 3: Figure S2. Effect of vistusertib on RTKs and downstream 744 
signalling pathways over a time course of 96 hours. MCF7 LTED
wt 
were treated for a 745 
time-course period of 24, 48, 72 and 96 hours with or without vistusertib (100nM) in the 746 
presence or absence of E2 (0.01nM).  747 
 748 
Additional File 4: Figure S3. Effect of vistusertib in ER-mediated transcription. 749 
MCF7, MCF7 LTED
wt 
and MCF7 LTED
Y537C
 were treated in the absence of E2 with 750 
vehicle or vistusertib for 24 hours and effects on TFF1, PGR, GREB1 and PDZK1 were 751 
assessed by RT-qPCR (n=2 biological and n=3 technical replicates). Error bars represent 752 
means ± SEM. Note, as MCF7 LTED
wt
 do not express PGR, this was excluded from the 753 
analysis. 754 
 755 
Additional File 5: Figure S4. Effect of vistusertib alone or in combination with 756 
fulvestrant on tumour progression in HBCx34 OvaR PDX models. (a) Assessment of 757 
tumour volume in individual animals treated with vehicle, fulvestrant, vistusertib or the 758 
combination. 759 
 760 
Additional File 6: File S1. Ingenuity pathway analysis of the HBCx34 OvaR PDX 761 
models at the end of the study 762 
 763 
Additional File 7: Figure S5. Representative immunohistochemistry images of (a) 764 
expression of Ki67, mTOR, pAKT
ser473
, p4EBP1, pS6 and pERK1/2 and (b) pEGFR 765 
and pIGF1R in HBCx22 OvaR PDX models following treatment for a period of 4 766 
 33 
days with either vehicle, vistusertib (Vist), fulvestrant (Fulv) or the combination of 767 
both (Vist + Fulv).  768 
